Valneva's 15min chart sees KDJ Golden Cross, Bullish Marubozu trend.

According to Valneva's 15-minute chart, a key technical indicator, the KDJ Golden Cross, was triggered on October 9, 2025 at 15:15. This bullish signal suggests that the momentum of the stock price is shifting towards the upside and has the potential to further increase. Furthermore, the presence of a Bullish Marubozu candlestick pattern reinforces the notion that buyers are in control of the market and that bullish momentum is likely to continue.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has recently strengthened its financial position by securing a new debt facility with Pharmakon Advisors, LP. The new debt facility, worth up to $500 million, extends the repayment period from Q1 2026 to Q4 2030, lowers the interest rate, and provides access to additional capital for future business development Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates^[1].

The company has also adjusted its 2025 financial guidance. Product sales are now expected between €155-170 million, down from the previous projection of €170-180 million. Total revenues are anticipated to reach €165-180 million, and total R&D investments are reduced to between €80-90 million Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates^[1]. Despite the downward revision, Valneva's commercial operations are expected to remain cash flow positive.

Valneva's stock price has been affected by the FDA suspension of the product license for its IXCHIQ vaccine, leading to a 6.4% drop on Tuesday, October 6, 2025 Valneva Shares Slide After FDA Suspension Prompts Guidance Revision^[2]. However, technical indicators suggest a potential bullish trend. According to the 15-minute chart, a key technical indicator, the KDJ Golden Cross, was triggered on October 9, 2025, at 15:15. This bullish signal indicates that the momentum of the stock price is shifting towards the upside Valneva Shares Slide After FDA Suspension Prompts Guidance Revision^[2]. Additionally, the presence of a Bullish Marubozu candlestick pattern reinforces the notion that buyers are in control of the market and that bullish momentum is likely to continue.

The new debt facility and the technical indicators suggest that Valneva is well-positioned to navigate the challenges ahead and capitalize on future opportunities in the vaccine market.